CommentInhaled corticosteroids in COPD and the risk of pneumonia
References (16)
- et al.
COPD exacerbations: defining their cause and prevention
Lancet
(2007) - et al.
Budesonide and the risk of pneumonia: a meta-analysis of individual patient data
Lancet
(2009) - et al.
Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network
Semin Respir Crit Care Med
(2009) - et al.
COPD is associated with increased mortality in patients with community-acquired pneumonia
Eur Respir J
(2006) - et al.
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
N Engl J Med
(2007) - et al.
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide
Am J Respir Crit Care Med
(2008) - et al.
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease
Am J Respir Crit Care Med
(2007) - et al.
Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia
Am J Respir Crit Care Med
(2007)
Cited by (18)
Chronic obstructive pulmonary disease
2012, Revue des Maladies Respiratoires ActualitesDrugs that act on the respiratory tract
2011, Side Effects of Drugs AnnualCitation Excerpt :Pneumonia was not a primary outcome in any of the included studies and the criteria used to make a diagnosis were not stringent, with no requirement for radiological confirmation. Furthermore, it has been argued [7r] that many of the analyses did not have access to adequate baseline patient data, leading to difficulties in excluding potential confounders. Whether there are differences in the risk of pneumonia between various subclasses of inhaled glucocorticoids remains to be determined.
Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD
2010, Respiratory MedicineCitation Excerpt :The study duration and follow-up in the other meta-analyses were 6–40 months14 and 6–36 months.13 Due to the seasonal variation in the incidence of community acquired pneumonia a longer follow-up period may have noted more cases of pneumonia.21 The average years of follow-up per person, or time to pneumonia, was 1.49 years in our study with the endpoint being pneumonia hospitalization, death, or one year after the final date of the inclusion period.
Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
2023, Cochrane Database of Systematic ReviewsLow incidence of pneumonia in COPD patients treated with inhaled corticosteroids undergoing pulmonary rehabilitation
2018, Clinical and Molecular AllergyIncreased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease
2016, International Journal of COPD